Effects of Recombinant Human Growth Hormone in Children with Crohn’s Disease on the Muscle-Bone Unit: A Preliminary Study

2018 ◽  
Vol 90 (2) ◽  
pp. 128-131 ◽  
Author(s):  
Mabrouka A. Altowati ◽  
Sheila Shepherd ◽  
Paraic McGrogan ◽  
Richard K. Russell ◽  
S. Faisal Ahmed ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Bone Mineral ◽  
Human Growth Hormone ◽  
Lean Mass ◽  
Recombinant Human Growth Hormone ◽  
Human Growth ◽  
Mineral Density ◽  
The Impact

Background/Aims: There is limited information on the impact of recombinant human growth hormone (rhGH) on the muscle-bone unit in children with Crohn’s disease (CD). In this pilot study, we report on the effects of rhGH on bone formation, dual-energy X-ray absorptiometry (DXA) total body (TB) bone mineral density adjusted for height and lumbar spine (LS) bone mineral apparent density (BMAD), and body composition. Methods: Prospective study of 8 children with CD (6 male), aged 14.8 years (9.0–16.4), who received rhGH for 24 months. Serum procollagen type 1 N-terminal propeptide (P1NP) was measured at baseline and at 6 months. DXA was performed every 6 months. Results: Six months of rhGH led to improvement in P1NP SDS adjusted for bone age from –3.6 (–7.9 to –0.9) to –2.4 (–3.7 to 0.4) (p = 0.01). At baseline, reduction in LS-BMAD and TB lean mass SDS was observed being –1.2 (–3.6 to 0.8) (p = 0.01 vs. zero) and –0.8 (–2.4 to 3.0) (p = 0.11 vs. zero), respectively. No significant changes were seen in DXA bone and muscle parameters over the 24 months. Conclusion: Twenty-four months of therapy with rhGH in CD did not lead to an improvement in DXA BMD and lean mass, despite improvement in P1NP and linear growth.

Ileal perforation in a patient with Crohn’s disease while receiving recombinant human growth hormone therapy

2006 ◽  
Vol 22 (8) ◽  
pp. 983-984 ◽  
Author(s):  
Gernot W. Wolkersdörfer ◽  
Stephan Miehlke ◽  
Ralph Schneider ◽  
Gerhard Ehninger ◽  
Ingolf Schiefke ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Hormone Therapy ◽  
Human Growth Hormone ◽  
Growth Hormone Therapy ◽  
Recombinant Human Growth Hormone ◽  
Human Growth ◽  
Ileal Perforation

scholarly journals Impact of recombinant human growth hormone (rh-GH) treatment on psychiatric, neuropsychological and clinical profiles of GH deficient adults: a placebo - controlled trial

1999 ◽  
Vol 57 (2A) ◽  
pp. 182-189 ◽  
Author(s):  
CLÁUDIO DE NOVAES SOARES ◽  
NINA ROSA MUSOLINO ◽  
MALEBRANCHE CUNHA NETO ◽  
MARIA ADELAIDE CAIRES ◽  
MARIA CRISTINA ROSENTHAL ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Body Mass ◽  
Human Growth Hormone ◽  
Controlled Trial ◽  
Recombinant Human Growth Hormone ◽  
Human Growth ◽  
Hamilton Depression Scale ◽  
Gh Therapy ◽  
The Impact ◽  
Better Than

BACKGROUND: Untreated GH-deficient adults have a diversity of dysfunctions (e.g. reduced muscle strength, emotional instability during stress, depressive symptoms) that may cause deleterious effects on quality of life, and may be positively influenced by recombinant human growth hormone (rh-GH) therapy. AIM: To evaluate the impact of a clinical intervention with rh-GH therapy on GH - deficient adults. METHOD: The physical, psychiatric and neuropsychological status of 9 GH-deficient adults was determined before and after the administration of rh-GH (0.250 IU/Kg/week) in a double blind placebo-controlled trial for six months. Patients then received rh-GH for a further period of 6 months and their status was re-evaluated. RESULTS: Rh-GH was significant better than placebo at 6th month (p<0.05), producing increased serum Insulin like growth factor-I (IGF-1) levels, reduced body mass index (BMI) and body fat, increased lean body mass and water, reduced waist/hip ratio and increased energy expenditure. The rh-GH therapy was also significantly better than placebo on depressive features as measured by the Hamilton Depression Scale (17-items) (p= 0.0431) and the Beck Depression Inventory (p= 0.0431). Neuropsychological evaluations showed significant improvements in measures of Attention: Digit Backward (p= 0.035),Verbal Fluency (FAS) (p= 0.02) and Cognitive Efficiency (WAIS-R tests): Vocabulary (p= 0.027) , Picture Arrangements (p= 0.017), and Comprehension (p= 0.01) following rh-GH therapy. CONCLUSION: The clinical, psychiatric, and neuropsychological impairments of untreated GH-deficient adults can be decreased by rh-GH therapy.

scholarly journals ESR1 Gene Variants Are Predictive of Osteoporosis in Female Patients with Crohn’s Disease

2019 ◽  
Vol 8 (9) ◽  
pp. 1306
Author(s):  
Iwona Krela-Kaźmierczak ◽  
Marzena Skrzypczak-Zielińska ◽  
Marta Kaczmarek-Ryś ◽  
Michał Michalak ◽  
Aleksandra Szymczak-Tomczak ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Femoral Neck ◽  
Bone Mineral ◽  
P Value ◽  
Mineral Density ◽  
Female Patients ◽  
Esr1 Gene ◽  
The Impact

Decreased bone mass in patients with inflammatory bowel diseases (IBD) is a clinical problem with extremely severe consequences of osteoporotic fractures. Despite its increasing prevalence and the need for mandatory intervention and monitoring, it is often ignored in IBD patients’ care. Determining the biomarkers of susceptibility to bone mineral density disorder in IBD patients appears to be indispensable. We aim to investigate the impact of estrogen receptor gene (ESR1) gene polymorphisms on bone mineral density (BMD) in patients with ulcerative colitis (UC) and Crohn’s disease (CD), as they may contribute both, to osteoporosis and inflammatory processes. We characterised 197 patients with IBD (97 with UC, 100 with CD), and 41 controls carrying out vitamin D, calcium and phosphorus serum levels, and bone mineral density assessment at the lumbar spine and the femoral neck by dual-energy X-ray absorptiometry (DXA), ESR1 genotyping and haplotype analysis. We observed that women with CD showed the lowest bone density parameters, which corresponded to the ESR1 c.454-397T and c.454-351A allele dose. The ESR1 gene PvuII and XbaI TA (px) haplotype correlated with decreased femoral neck T-score (OR = 2.75, CI = [1.21–6.27], P-value = 0.016) and may be predictive of osteoporosis in female patients with CD.

Sign in / Sign up

Export Citation Format

Share Document